Radiolabelling and preclinical characterisation of [⁸⁹Zr]Zr-Df-ATG-101 bispecific to PD-L1/4-1BB.

ABSTRACT:

Purpose

ATG-101, a bispecific antibody that simultaneously targets the immune checkpoint PD-L1 and the costimulatory receptor 4-1BB, activates exhausted T cells upon PD-L1 crosslinking. Previous studies demonstrated promising anti-tumour efficacy of ATG-101 in preclinical models. Here, we labelled ATG-101 with ⁸⁹Zr to confirm its tumour targeting effect and tissue biodistribution in a preclinical model. We also evaluated the use of immuno-PET to study tumour uptake of ATG-101 in vivo.

Methods

ATG-101, anti-PD-L1, and an isotype control were conjugated with p-SCN-Deferoxamine (Df). The Df-conjugated antibodies were radiolabelled with ⁸⁹Zr, and their radiochemical purity, immunoreactivity, and serum stability were assessed. We conducted PET/MRI and biodis

SUBMITTER: Cao Z 

PROVIDER: S-EPMC11368977 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature